A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)

Active:	No
Cancer Type:	Hematopoietic Malignancies Lymphoma Non-Hodgkin Lymphoma Unknown Primary	NCT ID:	NCT05403450
Trial Phases:	Phase I Phase II	Protocol IDs:	ASTX660-03 (primary) NCI-2022-10432 2021-005338-40
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Taiho Pharmaceutical Company Limited
NCI Full Details:	http://clinicaltrials.gov/show/NCT05403450

Summary

The primary purpose of the study is to assess safety, and to identify the recommended
phase 2 dose (RP2D) of tolinapant in combination with oral decitabine/cedazuridine in
Phase 1 and to assess preliminary efficacy as determined by overall response rate (ORR)
in Phase 2.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.